Navigation Links
Pivotal Phase 3 Data from Boehringer Ingelheim Hepatitis C Portfolio to be Presented at 64th Annual AASLD Meeting
Date:10/1/2013

ral commonly used medications. Also, they offer insight into the clinical profile of the compounds for researchers and healthcare professionals looking for potential new treatment options for patients with HCV.

"We are pleased to see the presentation of the final results from STARTVerso1, 2 and 3, Boehringer Ingelheim's pivotal Phase 3 program in our hepatitis C portfolio, as well as other important analyses evaluating various patient subgroups at this year's AASLD meeting," said Peter Piliero, M.D., Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "These data, combined with that of our interferon-free trial, SOUND-C3, are evidence of our commitment to researching new therapeutic options for patients infected with HCV."

Faldaprevir and deleobuvir are investigational compounds and not approved by the FDA. Their safety and efficacy have not been established.

Boehringer Ingelheim's abstracts can be accessed on the AASLD website today at www.aasld.org.

Poster PresentationsTitleLead Author Presentation Details Effect of multiple oral doses of

faldaprevir on the multiple dose

pharmacokinetics of a combination

oral tablet of ethinylestradiol and

levonorgestrel in healthy

premenopausal female volunteers

J. Sabo

ID# 482
Session: HCV Therapy: The
Developmental Pipeline
Date: Sat, Nov. 2
Time: 2:00 PM – 7:30 PM ET
Location: Poster Hall Mass balance, metabolic profile

and the role of hepatic and

bacterial enzymes in the

metabolism of the HCV

polymerase inhibitor, deleobuvir

(BI 207127)

R. Sane

ID# 491
Session: HCV Therapy: The
Developmental Pipeline
Date: Sat, Nov. 2
Time: 2:00 PM – 7:30 PM ET
Location: Poster Hall Pharmacokinetics, safety, and
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. EntreMed Initiates Crossover Bioavailability And Food Effect Study Of ENMD-2076 Dosage Form To Be Used For Pivotal/Registration Clinical Trials
2. Shield Therapeutics Completes Recruitment to Pivotal Phase 3 Programme for Treatment of Iron Deficiency
3. CSL Behring Doses First Patient in Part 3 of Global Phase I/III Pivotal Study of rVIII-SingleChain (Recombinant Single-Chain Factor VIII) for Treatment of Hemophilia A
4. Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain
5. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
6. Relievant Medsystems Achieves Completion of Interim Safety Data Analysis of Intracept in SMART Pivotal Study and Expands Senior Leadership Team
7. Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress
8. Venaxis Advances Pivotal U.S. Study and Accelerates European Market Development for APPY1 Blood-based Appendicitis Test
9. AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
10. First U.S. Patients Treated in PneumRx RENEW Pivotal Study for Treatment of Severe Emphysema
11. ADVENTRX Initiates Pivotal Phase 3 Study of ANX-188
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... -- Amgen (NASDAQ: AMGN ) today announced the appointment of ... Pincus LLC, to the Amgen Board of Directors. ... and the deep, global experience he brings in the biopharmaceuticals ... , chairman and chief executive officer of Amgen. "Fred,s breadth of ... Mr. Hassan has been Partner and Managing Director ...
(Date:7/30/2015)...  Cleveland Clinic President Wael Barsoum , M.D. ... that industry is compelled to adopt declining reimbursements throughout ... develop the transformational innovations -- required to thrive in ... by Doug Kohrs , past President and CEO ... that industry must add "episode of care," also known ...
(Date:7/30/2015)... July 30, 2015  Growth of the U.S. nonprescription ... bring former prescription users to the OTC market. Due ... forecasts robust Rx-to-OTC switch activity over the next five ... with many new brands entering the market into existing ... next five years (even those with low to moderate ...
Breaking Medicine Technology:Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... YORK, July 19, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0574348/European-Medical-Displays-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging This research ... market in terms of the challenges faced ...
... drug companies face a number of obstacles to commercialize ... (FDA) and GMP compliance, to distribution agreements and the ... must be coordinated.  Those issues have just become easier ... VPCI have entered into a joint association.  The collaboration ...
Cached Medicine Technology:European Medical Displays Markets 2European Medical Displays Markets 3European Medical Displays Markets 4Spanish Drug Companies Have New Support Option for the U.S. Market 2
(Date:7/31/2015)... York, New York (PRWEB) , ... July 31, 2015 , ... ... to strut their stuff, Super-Sod debuted their new type of sod called Leisure ... registered trademark application in process. , To commemorate introduction of this new type of ...
(Date:7/31/2015)... ... ... Super Bowl 50 will emanate from Levi’s Stadium in Santa Clara, CA on ... Super Bowl. In the two weeks that separate the conference championships and the Super Bowl, ... Bowl game will mark the 50th time it has been held and the festivities will ...
(Date:7/31/2015)... ... July 31, 2015 , ... Precision Aesthetics is New York’s only ... was also the first provider of Exilis non-surgical fat reduction in New York. ... has attracted a large International clientele. Many patients travel to New York to ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... new store run by GoodThreads. The store can be accessed by visiting ... many of which are customizable. The best part: whenever a product is purchased, ...
(Date:7/31/2015)... ... July 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics announces the ... Zeltiq Aesthetics released this new applicator in the United States as an upgrade ... outer thighs. The original applicator required a 2 hour treatment time. The ...
Breaking Medicine News(10 mins):Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3
... Philadelphia, PA Louis J. Soslowsky, Ph.D. Fairhill ... director of the McKay Orthopaedic Research Laboratory and ... of Pennsylvania School of Medicine, was named the ... Delta Award by the American Academy of Orthopaedic ...
... ... at Johns Hopkins Medical Institutions, the Karolinska University Hospital and Institute, and The Feinstein ... , ... (Vocus) March 10, 2010 -- An experimental thyroid drug reduces cholesterol without the troublesome ...
... ... Improves Team Collaboration and Efficiency , ... San Francisco, CA (PRWEB) March 10, 2010 -- Manymoon announced today ... in the Google Apps Marketplace™, Google,s recently launched online storefront for Google Apps™ products ...
... , ... , ... ... ANN ARBOR, Mich. , March 10 Many Americans will lose an hour of sleep on March 14 ...
... Discovery in mouse study may someday extend men,s lives, ... therapy has proven useful in treating late-stage prostate cancer, ... tumors that are resistant to such therapy. , Now, ... a mechanism by which the secondary tumors gain their ...
... ... Recognized for PrescriptionDrugs.com Business Plan , ... Boston, MA (PRWEB) March 11, 2010 -- A week from today, ... ever HBS Alumni New Venture Contest . PrescriptionDrugs.com co-founder Mike “Zappy” Zapolin will ...
Cached Medicine News:Health News:Penn researcher, Louis J. Soslowsky, PhD, winner of the AAOS Kappa Delta Ann Doner Vaughan Award 2Health News:Penn researcher, Louis J. Soslowsky, PhD, winner of the AAOS Kappa Delta Ann Doner Vaughan Award 3Health News:Thyroid Hormone Analogue for Treating High Cholesterol 2Health News:Thyroid Hormone Analogue for Treating High Cholesterol 3Health News:Manymoon Now Available Through the Google Apps Marketplace 2Health News:Manymoon Now Available Through the Google Apps Marketplace 3Health News:Daylight-Saving Time Switch May Leave You Sleepy, U-M Physician Says 2Health News:Daylight-Saving Time Switch May Leave You Sleepy, U-M Physician Says 3Health News:Daylight-Saving Time Switch May Leave You Sleepy, U-M Physician Says 4Health News:Scientists Find Key to Hormone-Resistant Prostate Tumors 2Health News:Scientists Find Key to Hormone-Resistant Prostate Tumors 3Health News:PrescriptionDrugs.com and Mike “Zappy” Zapolin Have Been Selected to Compete in Harvard Business School New Venture Contest 2Health News:PrescriptionDrugs.com and Mike “Zappy” Zapolin Have Been Selected to Compete in Harvard Business School New Venture Contest 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: